In patients with non-small cell lung cancer, a lower level of baseline IL6 determines the response towards the PD1/PDL1 inhibition, suggesting that combining the two therapies will improve the effectiveness of fighting cancer [225]. The gene discussed is IL6; the disease is non-small cell lung carcinoma.